• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy.

作者信息

Amery Taylor, Tabatabaei Shaadi, Sonpatki Maya, Yu Evan Y, Beer Tomasz M

机构信息

Division of Medical Oncology, Oregon Health & Science University, Portland, OR, U.S.A.;

Division of Medical Oncology, Oregon Health & Science University, Portland, OR, U.S.A.

出版信息

Anticancer Res. 2024 May;44(5):2247-2248. doi: 10.21873/anticanres.17033.

DOI:10.21873/anticanres.17033
PMID:38677728
Abstract
摘要

相似文献

1
MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy.接受多西他赛治疗且病情进展的患者使用单胺氧化酶A抑制剂加用多西他赛的情况
Anticancer Res. 2024 May;44(5):2247-2248. doi: 10.21873/anticanres.17033.
2
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.在第二代激素治疗后，将卡铂加入转移性去势抵抗性前列腺癌的化疗方案中：对治疗反应和生存结局的影响。
Prostate. 2020 Oct;80(14):1216-1222. doi: 10.1002/pros.24048. Epub 2020 Jul 31.
3
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.多西他赛、泼尼松和帕唑帕尼治疗转移性去势抵抗性前列腺癌男性患者的 1b 期临床试验。
Prostate. 2019 Nov;79(15):1752-1761. doi: 10.1002/pros.23899. Epub 2019 Sep 9.
4
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).泮托拉唑通过自噬影响多西他赛耐药途径（PANDORA）：高剂量泮托拉唑（自噬抑制剂）联合多西他赛治疗转移性去势抵抗性前列腺癌（mCRPC）的 II 期试验。
Oncologist. 2019 Sep;24(9):1188-1194. doi: 10.1634/theoncologist.2018-0621. Epub 2019 Apr 5.
5
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.化疗诱导的前列腺癌单胺氧化酶表达作为一种细胞保护抗性酶发挥作用，并与临床结果相关。
PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.
6
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.转移性去势抵抗性前列腺癌的进展：多西他赛治疗后空间中治疗干预的影响。
J Hematol Oncol. 2011 Apr 23;4:18. doi: 10.1186/1756-8722-4-18.
7
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.帕博利珠单抗联合多西他赛和泼尼松在转移性去势抵抗性前列腺癌患者中的应用：来自 1b/2 期 KEYNOTE-365 队列 B 研究的长期结果。
Eur Urol. 2022 Jul;82(1):22-30. doi: 10.1016/j.eururo.2022.02.023. Epub 2022 Apr 6.
8
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.多中心、随机 II 期临床试验：多西他赛联合泼尼松加或不加 Cediranib 治疗化疗初治转移性去势抵抗性前列腺癌男性患者。
Oncologist. 2019 Sep;24(9):1149-e807. doi: 10.1634/theoncologist.2019-0331. Epub 2019 May 31.
9
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.CONTACT-01 研究：阿替利珠单抗+卡博替尼对比多西他赛用于晚期非小细胞肺癌患者二线治疗的随机 III 期研究
J Clin Oncol. 2024 Jul 10;42(20):2393-2403. doi: 10.1200/JCO.23.02166. Epub 2024 Mar 29.
10
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.先前接受过基于多西他赛化疗的转移性去势抵抗性前列腺癌：来自PROXIMA前瞻性注册研究的治疗模式
J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.18.00009.

引用本文的文献

1
Targeting monoamine oxidases in cancer: advances and opportunities.癌症中靶向单胺氧化酶：进展与机遇
Trends Mol Med. 2025 May;31(5):479-491. doi: 10.1016/j.molmed.2024.09.010. Epub 2024 Oct 21.